RxDoctor Payments DataLook up a doctor →

Ratnesh Kumar, MD

Internal Medicine · Lenexa, KSNPI 1194750828

Payments from drug & device makers

$8,547in general payments, 2019–2025

Across 532 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$900
  • Lilly USA, LLC$767
  • Pfizer$654
  • Novo Nordisk$588
  • Amgen$320
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$8,547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,547 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$48,470
Medicare patients
153
Services billed
4,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$17,791
JardianceEmpagliflozin15$12,696
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,931
OxycontinOxycodone Hcl22$6,751
GemtesaVibegron11$6,402
DayvigoLemborexant12$3,962
Dexlansoprazole DrDexlansoprazole12$1,886
Atorvastatin Calcium182$1,595
PaxlovidNirmatrelvir/Ritonavir12$1,335
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen75$1,247
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen52$1,241
Albuterol Sulfate HfaAlbuterol Sulfate54$1,172
Gabapentin71$895
Pantoprazole Sodium84$873
Fluticasone Propionate26$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$654$19,12631 claims
Boehringer IngelheimJardiance$251$12,69615 claims
GSKTrelegy Ellipta$153$11,93114 claims
Sumitomo Pharma America, Inc.Gemtesa$112$6,40211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$70555 claims
AbbVieSynthroid$2,029$59715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →